摘要:
The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
摘要:
The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
摘要:
The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
摘要:
Oxygen-containing heterocyclic compounds represented by general formula (I) or pharmacologically acceptable salts thereof, wherein R?1 and R2¿ are the same or different and each represents hydrogen, lower alkyl, cyano or -(CH¿2?)n-E-CO-F (wherein E represents a bond, O or NH; F represents OR?6 or NR7R8¿; and n is an integer of from 0 to 4), or R?1 and R2¿ together with the adjacent carbon atom may form a saturated carbocyclic ring, or R2 together with R?11 or R13¿, as will be described hereinbelow, may form a single bond; R3 represents hydrogen, phenyl or halogeno; R4 represents hydroxy, lower alkoxy, etc.; A represents -C(R9)(R10)- or O; B represents O, NR?11, -C(R12)(R13¿)- or -C(R?14)(R15)-C(R16)(R17¿)-; D represents (1) -C(R18)(R19)-X- [where X represents -C(R21)(R22)-, S or NR23], (2) -C(R19a)=Y- [wherein Y represents -C(R24)-Z-, {wherein Z represents CONH, CONHCH¿2? or a bond}, or N] or (3) a bond; and R?5¿ represents aryl, heteroaryl, cycloalkyl, pyridine-N-oxide, cyano or lower alkoxycarbonyl.
摘要:
An oxygen-containing heterocyclic compound represented by following Formula (I): wherein R 1 and R 2 independently represent hydrogen, lower alkyl, cyano, -(CH 2 ) n -E-CO-F (wherein E represents a bond, O, or NH; F represents OR 6 or NR 7 R 8 ; and n represents an integer of 0 to 4), or the like; R 1 and R 2 are combined to represent a saturated carbon ring together with a carbon atom adjacent thereto; or R 2 , and R 11 or R 13 described below are combined to form a single bond; R 3 represents hydrogen, phenyl, or halogen; R 4 represents hydroxy, lower alkoxy, or the like; A represents -C(R 9 )(R 10 )- or O; B represents O, NR 11 , -C(R 12 )(R 13 )-, or -C(R 14 )(R 15 )-C(R 16 )(R 17 )-; D represents (i) -C(R 18 )(R 19 )-X- (wherein X represents -C(R 21 )(R 22 )-, S, or NR 23 ), (ii) -C(R 19a )=Y- [Y represents -C(R 24 )-Z- (wherein Z represents CONH, CONHCH 2 , or a bond), or N], or (iii) a bond; and R 5 represents aryl, an aromatic heterocyclic group, cycloalkyl, pyridine-N-oxide, cyano, or lower alkoxycarbonyl; or a pharmaceutically acceptable salt thereof.
摘要:
Imidazoquinazoline derivatives represented by general formula (I) or pharmacologically acceptable salts thereof, wherein R 1 represents hydrogen, optionally substituted lower alkyl, etc.; R 2 and R 3 are the same or different and each represents hydrogen, optionally substituted lower alkyl, optionally substituted aralkyl, optionally substituted aryl, etc., or R 2 and R 3 together form an optionally substituted nitrogenous heterocycle; R 4 represents hydrogen or optionally substituted lower alkyl; X represents O or S; Y represents a single bond or O; and n is 0, 1, 2 or 3.
摘要:
These compounds are prepared by culturing bacteria belonging to the genus Streptomyces. They have antibacterial and oncostatic activities and are useful as medicines.
摘要翻译:新的cpds。 指定为DC-88A和DC-89A1。 通过Streptomyces物种的培养,特别是S.firidicus FERM-BP 988或小檗菌FERM-BP1002。DC-88A具有分子式C 26 H 25 N 3 O 8,mol。 重量。 (EI-MS)507.1624,为溶胶。 在甲醇,乙醇,丙酮,氯仿,乙酸乙酯,DMSO中; INSOL。 在水中,己烷。 使用甲苯/丙酮(7:3v / v)的硅胶上Rf值为0.46。 DC-89Al具有分子式C26H26N3O8Cl,mol。 重量。 543,m.pt 157.5-58.5℃; 溶胶。 在甲醇,乙醇,丙酮,乙酸乙酯,氯仿,DMSO中; INSOL。 在水,己烷,IR,UV,1 H NMR,13 C NMR光谱数据中给出了两种cpds。
摘要:
[1,2,4]Triazolo[1,5-c]pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A 2A receptor antagonism and are useful for the treatment or prevention of various diseases induced by hyperactivity of adenosine A 2A receptors (for example, Parkinson's disease or senile dementia): wherein R 1 represents substituted or unsubstituted aryl, or the like; R 2 represents hydrogen, halogen, lower alkyl, substituted or unsubstituted aryl, or the like; R 3 represents hydrogen, halogen, XR 10 (wherein X represents O or S; and R 10 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aralkyl, lower alkyl, or hydroxy lower alkyl), or the like; and Q represents hydrogen or 3,4-dimethoxybenzyl.
摘要翻译:提供了由式(I)表示的三氮唑-1,5-c嘧啶衍生物或其药学上可接受的盐,其具有腺苷A2A受体拮抗作用,并且可用于治疗或预防腺苷A2A受体多动症诱导的各种疾病(对于 例如,帕金森病或老年痴呆):其中R 1表示取代或未取代的芳基等; R 2表示氢,卤素,低级烷基,取代或未取代的芳基等; R 3表示氢,卤素,XR 10(其中X表示O或S; R 10表示取代或未取代的芳基,取代或未取代的芳族杂环,取代或未取代的芳烷基,低级烷基或羟基 低级烷基)等; Q表示氢或3,4-二甲氧基苄基。
摘要:
An imidazoquinazoline derivative represented by formula (I) or a pharmacologically acceptable salt thereof, wherein R 1 andR 2 may be the same or different from each other and each represents hydrogen, lower alkyl, lower alkenyl, aryl, etc.; R 3 represents hydrogen, lower alkyl, cycloalkyl, lower alkenyl, aryl, etc.; and X represents O or S. This compound has a potent and selective cCMP-specific PDE inhibitor activity and is useful for treating or mitigating cardiovascular diseases such as thrombosis, angina pectoris, hypertension and arteriosclerosis, asthma, and so forth.
摘要翻译:由式(I)表示的咪唑并喹唑啉衍生物或其药学上可接受的盐,其中R 1和R 2可以相同或不同,各自表示氢,低级烷基,低级烯基,芳基等; R 3表示氢,低级烷基,环烷基,低级烯基,芳基等; X表示O或S.该化合物具有有效和选择性的cCMP特异性PDE抑制剂活性,可用于治疗或缓解心血管疾病如血栓形成,心绞痛,高血压和动脉硬化,哮喘等。